From: French recommendations for the management of systemic sclerosis
Antinuclear antibody specificities | Appearance of fluorescence | % of patients | Form of the disease | Clinical phenotype |
---|---|---|---|---|
Anticentromere antibodies | Centromeric | 20–40% | Limited cutaneous SSc | PAH |
Severe peripheral vascular disease | ||||
Anti-Scl-70 or anti-topoisomerase antibodies | Homogeneous and nucleolar | 20–30% | Diffuse cutaneous SSc | Severe ILD |
Severe peripheral vascular disease | ||||
Anti-RNA polymerase III | Speckled (±nucleolar) | 20–25% in Caucasians of North America and the UK and about 5% in France, Germany, Italy, and Japan | Diffuse cutaneous SSc | Rapidly progressive skin damage |
Scleroderma renal crisis | ||||
Cancer | ||||
Anti-U3-RNP (antifibrillarin) | Nucleolar | In 4–10% | Diffuse cutaneous SSc  >  Limited cutaneous SSc | ILD |
PAH | ||||
Renal crisis | ||||
Digestive damage of small intestine | ||||
Anti-Th/To | Nucleolar | 2–5% | Limited cutaneous SSc | ILD |
PAH | ||||
Anti-Pm-Scl | Speckled and nucleolar | 2% | Limited cutaneous SSc (overlap with myositis) | Myositis |
Anti-U1 RNP | Speckled | Â | Limited cutaneous SSc (overlap with MCTD) | Arthritis |
Myositis | ||||
PAH | ||||
Anti-U11/U12 RNP | Speckled | 1–3% | Diffuse cutaneous SSc/limited cutaneous SSc | Severe ILD |
Anti-Ku | Speckled | Â | Limited cutaneous SSc (overlap syndrome with myositis) | Myositis |
Anti-RuvBL 1/2 | Speckled | 1–3% | Diffuse cutaneous SSc (overlap myositis) | Myositis |